Risk reduction of ASCVD attributed to lowering of remnant cholesterol from statins, fibrates, APOC3 inhibitors, and ANGPTL3 inhibitors: a cohort study
Overview
Paper Summary
This observational study suggests that lowering remnant cholesterol, as seen with new APOC3 and ANGPTL3 inhibitors, could reduce 10-year ASCVD risk by 2.7-4.1% in statin users and 1.4-2.1% in statin non-users with high remnant cholesterol. However, randomized controlled trials are needed to confirm these findings and establish causality.
Explain Like I'm Five
This study suggests that new cholesterol-lowering drugs could significantly reduce heart disease risk in people with high remnant cholesterol, but real-world trials are needed to confirm this.
Possible Conflicts of Interest
Anne Langsted received honoraria/consultancies from Amarin and Novartis and is currently employed by Novo Nordisk. Anette Varbo is also employed by Novo Nordisk. Børge G. Nordestgaard reports consultancies/talks for AstraZeneca, Sanofi, Ionis, Amgen, Amarin, Novartis, Novo Nordisk, Esperion, Lilly, Arrowhead, and Marea.
Identified Limitations
Rating Explanation
Strong methodology using a large cohort and registry data, but limitations inherent to observational studies prevent a higher rating. The declared conflicts of interest are also a concern.
Good to know
This is the Starter analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.
Explore Pro →